Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5448454 | 1.00 | HRH3 (0.60) | HRH3KDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL5434398 | 0.99 | KDM4E (0.60) | HRH3KDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL5418453 | 0.99 | KDM4E (0.60) | HRH3KDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL5418450 | 0.99 | KDM4E (0.60) | HRH3KDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL21026161 | 0.83 | KDM4E (0.53) | HRH3KDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL21025998 | 0.80 | ALDH1A1 (0.49) | HRH3KDM4EALDH1A1SMN1; SMN2MET | |
| SCHEMBL29313717 | 0.80 | ALDH1A1 (0.49) | HRH3KDM4EALDH1A1SMN1; SMN2MET | |
| SCHEMBL17053660 | 0.78 | ALDH1A1 (0.60) | HRH3KDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL3322292 | 0.78 | ALDH1A1 (0.50) | KDM4EALDH1A1KMT2AATMNPC1 | |
| SCHEMBL5444084 | 0.78 | KDM4E (0.57) | KDM4EALDH1A1SMN1; SMN2KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507484-B2 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20070213361-A1 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | KYOWA KIRIN CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| EP-1724271-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR NEUTROPHILIC INFLAMMATION DISEASE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213361-A1 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | MPO, MSR1, NR4A3 | HRH3 165/4885KDM4E 3941/4885ALDH1A1 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.